ArticleGastroenterology2008
A green tea component suppresses posttranslational expression of basic fibroblast growth factor in colorectal cancer.
Article in Gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Pooled it
- New insights into the role of ubiquitination in angiogenesis (Review).International journal of molecular medicine · 2025Review
- The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy.Frontiers in immunology · 2024Review
- Therapeutic effects of natural polyphenols on colorectal adenomas: Focus on preclinical studies (Review).Oncology reports · 2023Review
- Review
- Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activation.American journal of cancer research · 2023Article
- Protective effects and molecular mechanisms of tea polyphenols on cardiovascular diseases.Frontiers in nutrition · 2023Review
- Advances in the Antagonism of Epigallocatechin-3-gallate in the Treatment of Digestive Tract Tumors.Molecules (Basel, Switzerland) · 2019Review
- Microbiota facilitates the formation of the aminated metabolite of green tea polyphenol (-)-epigallocatechin-3-gallate which trap deleterious reactive endogenous metabolites.Free radical biology & medicine · 2019Article
- Epigallocatechin gallate inhibits hepatitis B virus via farnesoid X receptor alpha.Journal of natural medicines · 2016Article
- A multi-targeted approach to suppress tumor-promoting inflammation.Seminars in cancer biology · 2015Review
- Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention.American journal of physiology. Gastrointestinal and liver physiology · 2015Review
- Effects of tea polyphenols on proliferation and apoptosis of cadmium-transformed cells.International journal of clinical and experimental medicine · 2015Article
- Chemopreventive role of green tea in head and neck cancers.Integrative medicine research · 2014Review
- The involvement of endoplasmic reticulum stress in the suppression of colorectal tumorigenesis by tolfenamic acid.Cancer prevention research (Philadelphia, Pa.) · 2013Article
- Cyclin D1 degradation and p21 induction contribute to growth inhibition of colorectal cancer cells induced by epigallocatechin-3-gallate.Journal of cancer research and clinical oncology · 2012Article
- A novel local recycling mechanism that enhances enteric bioavailability of flavonoids and prolongs their residence time in the gut.Molecular pharmaceutics · 2012Article
- Phytochemicals and colorectal cancer prevention--myth or reality?Nature reviews. Gastroenterology & hepatology · 2011Article
- The role of antioxidant versus pro-oxidant effects of green tea polyphenols in cancer prevention.Molecular nutrition & food research · 2011Review
- Chemoprevention of intestinal polyps in ApcMin/+ mice fed with western or balanced diets by drinking annurca apple polyphenol extract.Cancer prevention research (Philadelphia, Pa.) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsGreen tea catechins are known to have anticarcinogenic effects. Epigallocatechin-3-gallate (EGCG) accounts for almost 50% of the total catechin content in green tea extract and has very potent antioxidant effects. EGCG also inhibits angiogenesis, possibly through the inhibition of proangiogenic factors including vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), which in turn, inhibits tumor growth and metastasis. However, the exact molecular mechanism by which EGCG suppresses bFGF expression is not known. Our objective was to elucidate the molecular mechanisms by which EGCG inhibits bFGF expression in colorectal cancer.
methodsWe examined posttranslational regulation of bFGF by EGCG in human colorectal cancer cells. We also examined bFGF in intestinal tumor formation of APC(Min/+) mice with and without catechin treatment.
resultsThe bFGF protein was quickly degraded in the presence of EGCG, but a proteasome inhibitor suppressed this degradation. EGCG was also found to increase ubiquitination of bFGF and trypsin-like activity of the 20S proteasome, thereby resulting in the degradation of bFGF protein. Furthermore, EGCG suppressed tumor formation in APC(Min/+) mice, compared with vehicle-treated mice, in association with reduced bFGF expression.
conclusionsThe ubiquitin-proteasome degradation pathway contributes significantly to down-regulation of bFGF expression by EGCG. Catechin compounds have fewer adverse effects than chemotherapeutic agents and hence can be used as proof-of-concept in cancer therapeutics to suppress growth and metastasis by targeting proteins such as bFGF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.